Actively Recruiting
Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor
Led by Deciphera Pharmaceuticals, LLC · Updated on 2025-11-05
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational study focuses on people with Tenosynovial Giant Cell Tumor (TGCT) who are treated with vimseltinib. Researchers aim to understand how vimseltinib is used in real-world settings, treatment patterns, and the health-related quality of life for participants receiving this medication. The study does not intervene in treatment decisions or change standard medical care. Participants will be part of a disease registry where data is collected without any additional treatments or changes to their ongoing care. The study observes participants who have been prescribed vimseltinib, including those who have started treatment within the last six months or are about to start. There is no specific treatment or placebo given as part of this study. During the study, researchers will collect data on how long participants remain on vimseltinib and the time until they stop treatment, with an estimated observation period of up to 12 months. Participants will provide information through medical records and consent forms. The study will monitor health outcomes and treatment duration without affecting participant care. Participation lasts up to one year, with ongoing data collection during this time.
CONDITIONS
Brief Title
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of TGCT according to medical records
- Prescribed vimseltinib following approved label requirements
- Decision to receive vimseltinib made, with treatment either not started or started less than 6 months before enrollment
- Provided informed consent and medical records release
You will not qualify if you...
- Received any other systemic treatment for TGCT within 6 months before starting vimseltinib
- Started vimseltinib treatment more than 6 months before enrollment
- Currently active in an interventional clinical trial of vimseltinib
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants who are prescribed vimseltinib are observed to understand their treatment experience and outcomes.
Regular assessments based on routine care and participant availability
Trial Site Locations
Total: 1 location
1
Synexus Clinical Research, US INC
Wilmington, North Carolina, United States, 28401
Actively Recruiting
Research Team
C
Clinical Team
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here